I am practicing Molecular Docking using PyRx software. I tried to confirm whether my docking is appropriate or not by using available crystal structure of a CDK2-dinaciclib (enzyme-inhibitor complex) in the PDB database. After preparing my protein and ligand separately, i tried the docking. I found certain poses but none of them match with the binding mode described in the reported crystal structure. My questions are :-

1) Is it possible to achieve the same binding mode in PyRx Vs PDB crystal structure

2) In my docking out put, why is the inhibitor/dinaciclib binding at different binding site (too far from the proposed conventional binding site i.e hinge region of the same kinase). My compounds are analogues of dinaciclib or similar drugs which are expected to dock in the same region of the kinase)

3) Is it inappropriate not to select an active site of the the kinase/CDK2 during docking using PyRx. If i have to select an active site to get best docking pose, how can i achieve this?

3) Finally, how accurate/acceptable is PyRx Vs alternative docking softwares like Maestro for instance during publication?

Thanks in advance for your responses !!!

More Dessalegn Gelayee's questions See All
Similar questions and discussions